Base de dados : MEDLINE Pesquisa : D02.540.576.500.992.630 [Categoria DeCS] Referências encontradas : 780 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 78

ir para página

1 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28324838 [Au] Autor: Yan Z; Lu G; Sun H; Ma B [Ad] Endereço: Key Laboratory of Integrated Regulation and Resource Development on Shallow Lakes of Ministry of Education, College of Environment, Hohai University, Nanjing 210098, China. [Ti] Título: Influence of multi-walled carbon nanotubes on the effects of roxithromycin in crucian carp (Carassius auratus) in the presence of natural organic matter. [So] Source: Chemosphere;178:165-172, 2017 Jul. [Is] ISSN: 1879-1298 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Carbon nanotubes are increasingly entering the aquatic environment and may interact with other co-existing contaminants, such as antibiotics. However, whether these interactions may affect their bioavailability in aquatic organisms is the subject of considerable debate. The primary objective of this study was to assess the risks arising from the coexistence of roxithromycin (ROX) and multi-walled carbon nanotubes (MWCNTs) in waters containing natural organic matter (NOM), focusing on the distribution and bioaccumulation of ROX in crucian carp (Carassius auratus), and the related biochemical status. There were no significant differences in ROX bioaccumulation in fish following exposure to ROX with and without NOM. However, the further addition of MWCNTs significantly facilitated the bioaccumulation of ROX in the liver (32-80%), gill (15-74%), intestine (51-113%), and bile (15-67%) in different exposure periods. Meanwhile, a 0.3-fold increase in the metabolic enzyme activity and oxidative stress in the liver were markedly accelerated by the co-exposed MWCNTs compared to ROX alone. The findings imply that the ROX adsorbed on MWCNTs may be a higher threat to fish than ROX alone. The high and fast release of ROX from MWCNTs in bile salts and serum albumin may contribute to the enhancement in bioaccumulation and bioactivity of ROX in fish with MWCNTs. [Mh] Termos MeSH primário: Carpas/metabolismo Nanotubos de Carbono/química Compostos Orgânicos/farmacologia Roxitromicina/farmacologia Poluentes Químicos da Água/química [Mh] Termos MeSH secundário: Animais Antibacterianos/farmacologia Ácidos e Sais Biliares/metabolismo Carpas/crescimento & desenvolvimento Brânquias/efeitos dos fármacos Brânquias/metabolismo Fígado/efeitos dos fármacos Fígado/metabolismo Estresse Oxidativo/efeitos dos fármacos Albumina Sérica/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 0 (Bile Acids and Salts); 0 (Nanotubes, Carbon); 0 (Organic Chemicals); 0 (Serum Albumin); 0 (Water Pollutants, Chemical); 21KOF230FA (Roxithromycin) [Em] Mês de entrada: 1706 [Cu] Atualização por classe: 170602 [Lr] Data última revisão: 170602 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170322 [St] Status: MEDLINE

2 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28119103 [Au] Autor: Csongradi C; du Plessis J; Aucamp ME; Gerber M [Ad] Endereço: Centre of Excellence for Pharmaceutical Sciences (Pharmacen), North-West University, Private Bag X6001, Potchefstroom 2520, South Africa. [Ti] Título: Topical delivery of roxithromycin solid-state forms entrapped in vesicles. [So] Source: Eur J Pharm Biopharm;114:96-107, 2017 May. [Is] ISSN: 1873-3441 [Cp] País de publicação: Netherlands [La] Idioma: eng [Ab] Resumo: Recently, considerable interest developed in using newer/improved antibiotics for the treatment of Acne vulgaris. During this study, different roxithromycin solid-state forms (i.e. crystalline and amorphous) were encapsulated into vesicle systems (niosomes, proniosomes, ufosomes and pro-ufosomes) for dermis targeted delivery. Characterization of the vesicles was done with transmission electron microscopy, light microscopy, droplet size, droplet size distribution, pH, zeta-potential and entrapment efficiency percentage. Finally, comparative release and topical diffusion studies were performed, to evaluate if targeted topical delivery was obtained and if the roxithromycin solid-state amorphous forms resulted in improved topical delivery. Vesicle systems containing different roxithromycin (2%) solid-state forms were successfully prepared and characterized. The vesicles showed optimal properties for topical delivery. All carrier systems had topical delivery to the epidermis-dermis, whilst no roxithromycin was found in the receptor compartment or stratum corneum-epidermis. The niosomes were the leading formulation and the two amorphous forms had better topical delivery than the crystalline form. Successful targeted delivery of roxithromycin was obtained in the dermis, where the activity against Propionibacterium acnes is needed. The amorphous forms seemed to have held their solid-state form during formulation and in the vesicles, showing improved topical delivery in comparison to the crystalline form. [Mh] Termos MeSH primário: Antibacterianos/administração & dosagem Roxitromicina/administração & dosagem [Mh] Termos MeSH secundário: Administração Tópica Vesículas Revestidas Cristalização Difusão Portadores de Fármacos Composição de Medicamentos Sistemas de Liberação de Medicamentos Seres Humanos Técnicas In Vitro Lipossomos Testes de Sensibilidade Microbiana Tamanho da Partícula Propionibacterium acnes/efeitos dos fármacos Pele/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 0 (Drug Carriers); 0 (Liposomes); 21KOF230FA (Roxithromycin) [Em] Mês de entrada: 1708 [Cu] Atualização por classe: 170815 [Lr] Data última revisão: 170815 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170126 [St] Status: MEDLINE

3 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28039274 [Au] Autor: Dolton MJ; D'Argenio DZ [Ti] Título: Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. [So] Source: J Antimicrob Chemother;72(4):1129-1136, 2017 Apr 01. [Is] ISSN: 1460-2091 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Objectives: The macrolide antibiotic roxithromycin has seen widespread clinical use for several decades; however, no population pharmacokinetic analysis has been published. Early studies indicated saturation of protein binding and absorption at doses within the approved range, which may impact pharmacodynamic target attainment since regimens of 150 mg twice daily and 300 mg once daily are used interchangeably in clinical practice. This study aimed to develop a population-based meta-analysis of roxithromycin pharmacokinetics, and utilize this model to inform optimal dosing regimens. Methods: Following an extensive search, roxithromycin pharmacokinetic data were collected or digitized from literature publications. Population pharmacokinetic modelling was undertaken with ADAPT. Dosing simulations were performed to investigate differences in exposure and pharmacodynamic target attainment between dosing regimens. Results: A two-compartment model with saturable absorption described the data ( n = 63); changes in free drug exposure were simulated using a saturable protein binding model. Simulations indicated that a 300 mg daily regimen achieves a 37% and 53% lower total or free AUC ( f AUC), respectively, compared with 150 mg twice daily. These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%). Conclusions: Roxithromycin displays saturable absorption and protein binding leading to lower exposure and lower target attainment at MICs ≥0.5 mg/L with widely used once-daily dosing regimens, indicating that twice-daily regimens may be preferable for pathogens less susceptible to roxithromycin. [Mh] Termos MeSH primário: Antibacterianos/farmacocinética Roxitromicina/farmacocinética [Mh] Termos MeSH secundário: Absorção Fisiológica Antibacterianos/administração & dosagem Feminino Seres Humanos Masculino Testes de Sensibilidade Microbiana Modelos Teóricos Ligação Proteica Roxitromicina/administração & dosagem [Pt] Tipo de publicação: JOURNAL ARTICLE; META-ANALYSIS [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 21KOF230FA (Roxithromycin) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170926 [Lr] Data última revisão: 170926 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170101 [St] Status: MEDLINE [do] DOI: 10.1093/jac/dkw553

4 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27884873 [Au] Autor: Patel RB; Patel NM; Patel MR; Solanki AB [Ad] Endereço: A.R. College of Pharmacy and G.H. Patel institute of Pharmacy, Vallabh Vidyanagar 388 120, Anand, India. [Ti] Título: Optimization of Robust HPLC Method for Quantitation of Ambroxol Hydrochloride and Roxithromycin Using a DoE Approach. [So] Source: J Chromatogr Sci;55(3):275-283, 2017 03 01. [Is] ISSN: 1945-239X [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The aim of this work was to develop and optimize a robust HPLC method for the separation and quantitation of ambroxol hydrochloride and roxithromycin utilizing Design of Experiment (DoE) approach. The Plackett-Burman design was used to assess the impact of independent variables (concentration of organic phase, mobile phase pH, flow rate and column temperature) on peak resolution, USP tailing and number of plates. A central composite design was utilized to evaluate the main, interaction, and quadratic effects of independent variables on the selected dependent variables. The optimized HPLC method was validated based on ICH Q2R1 guideline and was used to separate and quantify ambroxol hydrochloride and roxithromycin in tablet formulations. The findings showed that DoE approach could be effectively applied to optimize a robust HPLC method for quantification of ambroxol hydrochloride and roxithromycin in tablet formulations. Statistical comparison between results of proposed and reported HPLC method revealed no significant difference; indicating the ability of proposed HPLC method for analysis of ambroxol hydrochloride and roxithromycin in pharmaceutical formulations. [Mh] Termos MeSH primário: Ambroxol/análise Cromatografia Líquida de Alta Pressão/métodos Roxitromicina/análise [Mh] Termos MeSH secundário: Limite de Detecção Modelos Lineares Reprodutibilidade dos Testes Projetos de Pesquisa Comprimidos [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Tablets); 200168S0CL (Ambroxol); 21KOF230FA (Roxithromycin) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170906 [Lr] Data última revisão: 170906 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 161126 [St] Status: MEDLINE [do] DOI: 10.1093/chromsci/bmw182

5 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27611991 [Au] Autor: Qin Y; Xu W; Mo L; Li X; Ge B; Xiong J; Gao L; Xu P; Xue M [Ad] Endereço: Department of Pharmacology, Beijing Laboratory for Biomedical Detection Technology and Instrument, School of Basic Medical Sciences, Capital Medical University, Beijing, China. [Ti] Título: Comparison of Pharmacokinetics and Tissue Distribution Kinetics of Roxithromycin and Expression of CYP 3A1 between Pregnant Mice and Foetuses. [So] Source: Basic Clin Pharmacol Toxicol;120(2):146-151, 2017 Feb. [Is] ISSN: 1742-7843 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: The roxithromycin, macrolide antibiotics, is recommended for treating mycoplasma infection and has the potential to be administered to pregnant women who are susceptible to the infection. This study compared the pharmacokinetic properties and tissue distribution of roxithromycin among pregnant mice and their foetuses. We also determined the level of CYP3A1, a major enzyme for roxithromycin metabolism, in liver microsomes and investigated the placental transport properties of roxithromycin. Biosamples were collected from female mice at gestational day 17 after a single intragastric administration of roxithromycin. A sensitive and specific liquid chromatography-tandem mass spectroscopy method was developed to detect the drug concentration and to obtain kinetic data. The level of CYP3A1 was significantly lower in foetal liver compared with that in maternal liver according to Western blot data, suggesting a decreased metabolism and prolonged half-life of roxithromycin in the foetus. The tissue distributions of roxithromycin were similar between mother and foetus, indicating that the placental barrier did not block the transport of roxithromycin from mother to foetus. The current findings are consistent with the clinical efficacy of roxithromycin in both pregnant mothers and foetuses. Based on this study, it is feasible and reasonable to predict the transport properties of other lipophilic drugs during pregnancy. [Mh] Termos MeSH primário: Antibacterianos/farmacocinética Citocromo P-450 CYP3A/metabolismo Feto/metabolismo Fígado/enzimologia Roxitromicina/farmacocinética [Mh] Termos MeSH secundário: Administração Oral Animais Antibacterianos/administração & dosagem Área Sob a Curva Biotransformação Cromatografia Líquida de Alta Pressão Feminino Idade Gestacional Meia-Vida Troca Materno-Fetal Taxa de Depuração Metabólica Camundongos Endogâmicos ICR Microssomos Hepáticos/enzimologia Placenta/metabolismo Gravidez Roxitromicina/administração & dosagem Espectrometria de Massas por Ionização por Electrospray Espectrometria de Massas em Tandem Distribuição Tecidual [Pt] Tipo de publicação: COMPARATIVE STUDY; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 21KOF230FA (Roxithromycin); EC 1.14.14.1 (CYP3A1 protein, mouse); EC 1.14.14.1 (Cytochrome P-450 CYP3A) [Em] Mês de entrada: 1702 [Cu] Atualização por classe: 170227 [Lr] Data última revisão: 170227 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160910 [St] Status: MEDLINE [do] DOI: 10.1111/bcpt.12668

6 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27600436 [Au] Autor: Timocin T; Husunet MT; Valipour E; Norizadeh Tazehkand M; Celik R; Topaktas M; Ila HB [Ad] Endereço: a Department of Biology , Institute of Science, Cukurova University , Adana , Turkey. [Ti] Título: In vitro cytogenetic evaluation of the particular combination of flurbiprofen and roxithromycin. [So] Source: Drug Chem Toxicol;40(3):326-332, 2017 Jul. [Is] ISSN: 1525-6014 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Flurbiprofen (FLB) (anti-inflammatory and analgesic drug) and roxithromycin (RXM) (antibiotic) were widely used in world wide. This study deals with investigation of genotoxicity, cytotoxicity, and oxidative stress effects of a particular combination of these drugs in human cultured lymphocytes. Also, DNA damaging-protective effects of combination of these drugs were analyzed on plasmid DNA. Human lymphocytes were treated with different concentrations (FLB + RXM; 10 µg/mL + 25 µg/mL, 15 µg/mL + 50 µg/mL, and 20 µg/mL + 100 µg/mL) of the drugs following by study of their genotoxic and cytotoxic effects by analysis of cytokinesis-block micronucleus test and nuclear division index, respectively. The effect of the combination in aspect of anti-oxidative and DNA damaging activity was evaluated on Pet-22b plasmid. According to our results, the combination of FLB and RXM did not show a notable genotoxic effect on cells. Although each of the substances had been shown as a cytotoxic agent by previous researchers, in this research, the combination of these drugs did not exhibit any adverse effect on cell division. FLB had DNA protection effect against H O while in combination with RXM had not the same effect on the plasmid. [Mh] Termos MeSH primário: Antibacterianos/toxicidade Anti-Inflamatórios não Esteroides/toxicidade Dano ao DNA Flurbiprofeno/toxicidade Roxitromicina/toxicidade [Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem Antibacterianos/farmacologia Anti-Inflamatórios não Esteroides/administração & dosagem Anti-Inflamatórios não Esteroides/farmacologia Divisão Celular/efeitos dos fármacos Células Cultivadas Relação Dose-Resposta a Droga Interações Medicamentosas Feminino Flurbiprofeno/administração & dosagem Flurbiprofeno/farmacologia Seres Humanos Linfócitos/efeitos dos fármacos Linfócitos/patologia Masculino Micronúcleos com Defeito Cromossômico/induzido quimicamente Estresse Oxidativo/efeitos dos fármacos Plasmídeos Roxitromicina/administração & dosagem Roxitromicina/farmacologia Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents, Non-Steroidal); 21KOF230FA (Roxithromycin); 5GRO578KLP (Flurbiprofen) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170906 [Lr] Data última revisão: 170906 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160908 [St] Status: MEDLINE [do] DOI: 10.1080/01480545.2016.1223097

7 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27587274 [Au] Autor: Pei QM; Jiang P; Yang M; Qian XJ; Liu JB; Kim SH [Ad] Endereço: Department of Radiology, Tianjin Hospital of Integrated Traditional Chinese and Western Medicine, Tianjin, China. Electronic address: 34713316@qq.com. [Ti] Título: Roxithromycin inhibits VEGF-induced human airway smooth muscle cell proliferation: Opportunities for the treatment of asthma. [So] Source: Exp Cell Res;347(2):378-84, 2016 Oct 01. [Is] ISSN: 1090-2422 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Asthma is a chronic respiratory disease characterized by reversible airway obstruction with persistent airway inflammation and airway remodelling, which is associated with increased airway smooth muscle (ASM) mass. Roxithromycin (RXM) has been widely used in asthma treatment; however, its mechanism of action is poorly understood. Vascular endothelial growth factor (VEGF) has been implicated in inflammatory and airway blood vessel remodelling in patients with asthma, and shown to promote ASM cell proliferation. Here, we investigated the effect of RXM on VEGF-induced ASM cell proliferation and attempted to elucidate the underlying mechanisms of action. We tested the effect of RXM on proliferation and cell cycle progression, as well as on the expression of phospho-VEGF receptor 2 (VEGFR2), phospho-extracellular signal-regulated kinase 1/2 (ERK1/2), phospho-Akt, and caveolin-1 in VEGF-stimulated ASM cells. RXM inhibited VEGF-induced ASM cell proliferation and induced cell cycle arrest. Additionally, VEGF-induced ASM cell proliferation was suppressed by inhibiting the activity of ERK1/2, but not that of Akt. Furthermore, RXM treatment inhibits VEGF-induced activation of VEGFR2 and ERK and downregulation of caveolin-1 in a dose-dependent manner. RXM also inhibited TGF-ß-induced VEGF secretion by ASM cells and BEAS-2B cells. Collectively, our findings suggest that RXM inhibits VEGF-induced ASM cell proliferation by suppression of VEGFR2 and ERK1/2 activation and caveolin-1 down-regulation, which may be involved in airway remodelling. Further elucidation of the mechanisms underlying these observations should enable the development of treatments for smooth muscle hyperplasia-associated diseases of the airway such as asthma. [Mh] Termos MeSH primário: Asma/tratamento farmacológico Asma/patologia Pulmão/patologia Miócitos de Músculo Liso/patologia Roxitromicina/farmacologia Roxitromicina/uso terapêutico Fator A de Crescimento do Endotélio Vascular/farmacologia [Mh] Termos MeSH secundário: Caveolina 1/metabolismo Pontos de Checagem do Ciclo Celular/efeitos dos fármacos Proliferação Celular/efeitos dos fármacos MAP Quinases Reguladas por Sinal Extracelular/metabolismo Fase G1/efeitos dos fármacos Seres Humanos Miócitos de Músculo Liso/efeitos dos fármacos Miócitos de Músculo Liso/metabolismo Fosforilação/efeitos dos fármacos Fator de Crescimento Transformador beta/metabolismo Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Caveolin 1); 0 (Transforming Growth Factor beta); 0 (Vascular Endothelial Growth Factor A); 21KOF230FA (Roxithromycin); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2); EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) [Em] Mês de entrada: 1705 [Cu] Atualização por classe: 170515 [Lr] Data última revisão: 170515 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160903 [St] Status: MEDLINE

8 / 780

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 27209694 [Au] Autor: Aucamp ME; Csongradi C; Gerber M; Du Plessis J [Ti] Título: A novel RP-HPLC method for the detection and quantification of roxithromycin in topical delivery studies. [So] Source: Pharmazie;71(4):175-6, 2016 Apr. [Is] ISSN: 0031-7144 [Cp] País de publicação: Germany [La] Idioma: eng [Ab] Resumo: A novel HPLC method with UV detection for the identification and quantification of roxithromycin (ROX) during in vitro skin penetration studies has been developed and validated. The method proved to be simple and rapid with isocratic elution (flow rate: 1.0 mL/min) of ROX, using a C18 column and UV detection at 205 nm. The mobile phase consisted of 0.06 M potassium di-hydrogen orthophosphate buffer (pH adjusted to 7.4 with sodium hydroxide) and acetonitrile in a 50:50 (v/v) ratio. This method showed linearity across the concentration range of 5 - 1000 µg/mL with a correlation coefficient of 0.9999. An average recovery of 101.78% was obtained. Limit of detection (LOD) and lower limit of quantification (LLOQ) values proved that ROX can still be detected at a concentration level of 0.3 µg/mL and accurately quantified at a concentration of 0.5 µg/mL. The specificity testing during method validation proved that this method is suitable for the accurate detection and quantification of ROX even when combined with different compounds typically used during the formulation of topical delivery systems. [Mh] Termos MeSH primário: Antibacterianos/administração & dosagem Roxitromicina/análise [Mh] Termos MeSH secundário: Administração Tópica Cromatografia Líquida de Alta Pressão Sistemas de Liberação de Medicamentos Limite de Detecção Reprodutibilidade dos Testes Roxitromicina/administração & dosagem Espectrofotometria Ultravioleta [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 21KOF230FA (Roxithromycin) [Em] Mês de entrada: 1606 [Cu] Atualização por classe: 160523 [Lr] Data última revisão: 160523 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160524 [St] Status: MEDLINE

9 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27136613 [Au] Autor: Guo Q; Shi ZJ; Xu JL; Yang CC; Huang M; Shi ML; Jin RC [Ad] Endereço: College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 310036, China; Key Laboratory of Hangzhou City for Ecosystem Protection and Restoration, Hangzhou Normal University, Hangzhou 310036, China. [Ti] Título: Inhibition of the partial nitritation by roxithromycin and Cu(II). [So] Source: Bioresour Technol;214:253-8, 2016 Aug. [Is] ISSN: 1873-2976 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: To facilitate the application of partial nitritation (PN) - anaerobic ammonium oxidation process in nitrogen removal from livestock wastewater, the inhibition of roxithromycin (ROX) and Cu(II) on the PN sludge was examined using a respirometric method. The results showed that the IC50 of ROX and Cu(II) on PN sludge were 346 and 74.3mgL(-1), respectively. The relative specific respiration rate (SRR) of ammonia-oxidizing bacteria (AOB) decreased from 87.4% to 17.7% with the ROX concentration increased from 0 to 500mgL(-1). When the concentration of Cu(II) increased from 0 to 160mgL(-1), the SRRs of AOB and nitrite-oxidizing bacteria decreased by 85.5% and 11.2%, respectively. According to the isobole plots analysis, combined suppression by ROX and Cu(II) was synergistic. Fourier transform infrared spectroscopy analyses showed that ROX exposure altered the positions of CO bonds, and the intensity of the absorption peak at 2100cm(-1) changed under Cu(II) exposure. [Mh] Termos MeSH primário: Bactérias/metabolismo Cobre/farmacologia Roxitromicina/farmacologia Esgotos/microbiologia Eliminação de Resíduos Líquidos/métodos [Mh] Termos MeSH secundário: Compostos de Amônio/metabolismo Animais Antibacterianos/administração & dosagem Antibacterianos/farmacologia Bactérias/efeitos dos fármacos Reatores Biológicos/microbiologia Relação Dose-Resposta a Droga Sinergismo Farmacológico Concentração Inibidora 50 Gado Esterco Nitrogênio/isolamento & purificação Nitrogênio/metabolismo Roxitromicina/administração & dosagem Espectroscopia de Infravermelho com Transformada de Fourier Eliminação de Resíduos Líquidos/instrumentação Águas Residuais [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Ammonium Compounds); 0 (Anti-Bacterial Agents); 0 (Manure); 0 (Sewage); 0 (Waste Water); 21KOF230FA (Roxithromycin); 789U1901C5 (Copper); N762921K75 (Nitrogen) [Em] Mês de entrada: 1701 [Cu] Atualização por classe: 170116 [Lr] Data última revisão: 170116 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160503 [St] Status: MEDLINE

10 / 780

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27131266 [Au] Autor: Peters S [Ad] Endereço: St. Elisabeth Hospital Salzgitter, Germany. Electronic address: H.u.S.Peters@t-online.de. [Ti] Título: Proof of an association between Morbus Ebstein and arrhythmogenic cardiomyopathy in a patient with chronic atrial fibrillation. [So] Source: Int J Cardiol;215:436-7, 2016 Jul 15. [Is] ISSN: 1874-1754 [Cp] País de publicação: Netherlands [La] Idioma: eng [Mh] Termos MeSH primário: Fibrilação Atrial/diagnóstico Cardiomiopatias/diagnóstico por imagem Anomalia de Ebstein/diagnóstico por imagem Pneumonia/diagnóstico [Mh] Termos MeSH secundário: Idoso Arritmias Cardíacas/etiologia Dispneia/etiologia Ecocardiografia/métodos Feminino Seres Humanos Pneumonia/tratamento farmacológico Roxitromicina/uso terapêutico [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Nm] Nome de substância: 21KOF230FA (Roxithromycin) [Em] Mês de entrada: 1708 [Cu] Atualização por classe: 170817 [Lr] Data última revisão: 170817 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160501 [St] Status: MEDLINE

---

página 1 de 78

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde